Early versus delayed coronary angiography in patients with out-of-hospital cardiac arrest and no ST-segment elevation: a systematic review and meta-analysis of randomized controlled trials
verfasst von:
Fardin Hamidi, Elaaha Anwari, Christian Spaulding, Caroline Hauw-Berlemont, Aurélie Vilfaillot, Ana Viana-Tejedor, Karl B. Kern, Chiu-Hsieh Hsu, Brian A. Bergmark, Arman Qamar, Deepak L. Bhatt, Remo H. M. Furtado, Peder L. Myhre, Christian Hengstenberg, Irene M. Lang, Norbert Frey, Anne Freund, Steffen Desch, Holger Thiele, Michael R. Preusch, Thomas A. Zelniker
Recent randomized controlled trials did not show benefit of early/immediate coronary angiography (CAG) over a delayed/selective strategy in patients with out-of-hospital cardiac arrest (OHCA) and no ST-segment elevation. However, whether selected subgroups, specifically those with a high pretest probability of coronary artery disease may benefit from early CAG remains unclear.
Methods
We included all randomized controlled trials that compared a strategy of early/immediate versus delayed/selective CAG in OHCA patients and no ST elevation and had a follow-up of at least 30 days. The primary outcome of interest was all-cause death. Odds ratios (OR) were calculated and pooled across trials. Interaction testing was used to assess for heterogeneity of treatment effects.
Results
In total, 1512 patients (67 years, 26% female, 23% prior myocardial infarction) were included from 5 randomized controlled trials. Early/immediate versus delayed/selective CAG was not associated with a statistically significant difference in odds of death (OR 1.12, 95%-CI 0.91–1.38), with similar findings for the composite outcome of all-cause death or neurological deficit (OR 1.10, 95%-CI 0.89–1.36). There was no effect modification for death by age, presence of a shockable initial cardiac rhythm, history of coronary artery disease, presence of an ischemic event as the presumed cause of arrest, or time to return of spontaneous circulation (all P-interaction > 0.10). However, early/immediate CAG tended to be associated with higher odds of death in women (OR 1.52, 95%-CI 1.00–2.31, P = 0.050) than in men (OR 1.04, 95%-CI 0.82–1.33, P = 0.74; P-interaction 0.097).
Conclusion
In OHCA patients without ST-segment elevation, a strategy of early/immediate versus delayed/selective CAG did not reduce all-cause mortality across major subgroups. However, women tended to have higher odds of death with early CAG.
Dr. Michael R. Preusch and Dr. Thomas A. Zelniker contributed equally to this manuscript.
Background
Despite advances in resuscitation and critical care management, mortality rates in patients with out-of-hospital cardiac arrest (OHCA) remain high [1]. Although coronary artery disease and myocardial infarction are the most prevalent causes of OHCA, patients with OHCA and no ST-segment elevation constitute a heterogeneous group, making it challenging for clinicians to determine the appropriate indication and optimal timing of coronary angiography [2‐4]
Although early/immediate coronary revascularization may improve myocardial function and prevent cardiogenic shock or life-threatening arrhythmia in patients with an acute coronary syndrome [5], recent randomized controlled trials did not show benefit of early/immediate coronary angiography over a delayed/selective strategy in an OHCA patient population without ST-segment elevation [1, 6‐10]. However, it remains unclear whether some patients, such as those with a high pre-test probability of coronary artery disease, may benefit from an early or immediate strategy of coronary angiography [11]. Also, there is growing evidence of sex-based differences and disparities in patient characteristics, risk factors, management, and outcomes between men and women with OHCA. Women with OHCA are more likely to present with a non-shockable rhythm, to be older, have more comorbidities, are less likely to be resuscitated by bystanders, receive coronary angiography and targeted temperature management, and have poorer outcomes than men [11‐16].
Anzeige
Because no single trial has been powered to test for effect modification across subgroups, we aimed to pool data from all randomized controlled trials that compared an early/immediate versus a delayed/selective strategy of coronary angiography in OHCA patients without ST-segment elevation to obtain more reliable estimates overall and in relevant subgroups.
Materials and methods
Search strategy
The present meta-analysis was done using the methods proposed in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement (PRISMA-P) [17]. We performed a comprehensive data search of randomized-controlled trials that compared early/immediate versus delayed/selective coronary angiography with a follow-up time of at least 30 days in patients with OHCA and no ST-segment elevation from inception to 16.07.2022 on PubMed and EMBASE. Data search and extraction were conducted by 2 independent reviewers (F. H., E. A.) using a standardized data form, and any discrepancies were resolved by consensus or consulting a third reviewer (T. A. Z.). When endpoints (including those for subgroups) were not reported, the respective trial authors were contacted. The search algorithm is presented in detail in the appendix. Risk of bias was assessed using the Cochrane tool of risk of bias assessment Version 2 [18].
Outcomes
The primary outcome of interest was all-cause mortality. The secondary outcome of interest was the composite of all-cause death or neurological deficit (defined as a cerebral performance category score of more than 2) (Supplemental Table 1).
Statistical analysis
Pooled odds ratios (OR) and the corresponding 95% confidence intervals (CI) were calculated for the primary and secondary outcomes using a fixed effects model. In addition, sensitivity analyses were performed using random effect models by utilizing the method of residual maximum likelihood (REML) and Hartung-Knapp adjustment. We also performed subgroup analyses based on age, sex, presence of a shockable initial cardiac rhythm, history of coronary artery disease, presence of an ischemic event as the presumed cause of arrest, and time to return of spontaneous circulation (ROSC). We tested for treatment effect modification by subgroup using random effects models, applying the method of REML and Hartung-Knapp adjustment. We also conducted meta-regression analyses applying the method of REML according to baseline variables (including left-ventricular ejection fraction (LVEF), the proportion of patients with radial access for cardiac catheterization, the proportion of patients without clinically significant coronary artery disease, and the proportion of patients with three-vessel coronary artery disease) for death.
Anzeige
The Cochrane Q statistic and Higgins and Thompsons’ I2 were calculated to assess study heterogeneity. An I2 of less than 25% was considered to indicate low heterogeneity, 25% to 75% was considered to be moderate heterogeneity, and above 75% was considered to be high heterogeneity [19]. Publication-bias and small-study bias were assessed using funnel plots and Egger’s regression test. All reported P values are two-sided, and no adjustments for multiple testing were performed. All statistical analyses were performed using R version 4.2.0 (R Core Team, Vienna, Austria) and the R package metafor (version 3.4.0).
Results
Study population
In total, 1512 patients from 5 randomized controlled trials were included in the present meta-analysis (Fig. 1). All trials were well conducted and had a low risk of bias (Fig. S1). Funnel plots showed no significant publication bias (Fig. S2). The follow-up time of the primary trials ranged from 30 to 180 days. The weighted mean age was 67 years, and 394 (26%) patients were female (Table 1). In total, 255 (23%) had a prior myocardial infarction, and 286 (24%) had diabetes. The proportion of patients with an initial shockable rhythm ranged from 30% in the EMERGE trial to 100% in the COACT trial.
Fig. 1
Prisma flow diagram summarizing the search strategy and selection of trials
Time to CAG in the early/immediate treatment arm (hours)
2 (2–3)
2 (1–2)
3 (2–4)
3 (2–3)
2 (2–3)
2.4
Time to CAG in the delayed/selective treatment arm (hours)
122 (52–197)
60 (14–173)
47 (26–117)
129 (87–186)
66 (41–75)
81.6
PCI performed (%)
154/437 (35.2)
24/73 (32.9)
163/412 (39.6)
12/52 (23.1)
55/200 (27.5)
408/1174 (34.8)
Continuous variables are reported as medians (interquartile range) unless stated otherwise.
CAG coronary angiography, CPR cardiopulmonary resuscitation, PAD peripheral artery disease, ROSC return of spontaneous circulation, PCI percutaneous coronary intervention
*12 months data have been reported for death. Missing values have not been collected in the respective trials
×
Early/immediate versus delayed/selective coronary angiography
The median time to coronary angiography ranged from 2 to 3 h (weighted mean 2.4 h) in patients assigned to early/immediate coronary angiography, compared to 47–129 h (weighted mean 81.6 h) in patients assigned to a strategy of delayed/selective coronary angiography. Coronary revascularization was performed in 246 (34%) patients treated with early/immediate coronary angiography and in 162 (36%) patients treated with delayed/selective coronary angiography.
The primary outcome of all-cause death occurred in 367 patients of the 760 patients (48.3%) that were assigned to a strategy of early/immediate coronary angiography and in 343 patients of the 752 patients (45.6%) assigned to a strategy of delayed/selective coronary angiography, resulting in no significant difference in the odds of death (OR 1.12, 95% CI 0.91 to 1.38, P = 0.28, Fig. 2). The most common causes of death were anoxic brain injury (51.1%), followed by cardiovascular death (25.7%) and did not differ between the two treatment strategies (Supplemental Table 2). Baseline factors including LVEF, radial access for coronary angiography, the proportion of patients without significant coronary artery disease, and the presence of three-vessel coronary artery disease did not modify the effect of immediate/early versus delayed/selective coronary angiography on death in a meta-regression (P-interaction > 0.10 for each; Fig. S3).
Fig. 2
Pooled data for (A) all-cause death and (B) the composite outcome of all-cause death or neurological deficit. Legend: CAG coronary angiography; OR odds ratio; CI confidence interval
×
Similarly, there was no significant difference in the odds of the composite of all-cause death or neurological deficit (OR 1.10, 95% CI 0.89 to 1.36, P = 0.37). Sensitivity analyses, that included the DISCO pilot study (Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest) [6] with a follow-up of 24 h only, or using random effects models yielded similar results (Figs. S4 and S5).
Moreover, there was no significant difference in safety events, including the odds of bleeding (OR 0.94, 95% CI 0.52 to 1.70, P = 0.83; Fig. S6) and kidney events (OR 1.13, 95% CI 0.75 to 1.70, P = 0.55; Fig. S7) between early/immediate versus delayed/selective coronary angiography.
Subgroup analyses
Early/immediate (versus delayed/selective) coronary angiography tended to be associated with higher odds of death in women (OR 1.52, 95% CI 1.00 to 2.31, P = 0.050) than in men (OR 1.04, 95% CI 0.82 to 1.33, P = 0.74; P-value for interaction 0.097; Fig. 3). A qualitatively similar relationship, though statistically not significant, was found in younger patients, where early/immediate coronary angiography was associated with higher odds of death (OR 1.28, 95% CI 0.96 to 1.72), which was not seen in older patients (OR 0.93, 95% CI 0.67 to 1.29, P-value for interaction 0.31). There was no evidence of effect modification for all-cause death across tested subgroups, including the presence or absence of an initial shockable cardiac rhythm, history of coronary artery disease, presence of an ischemic event as the presumed cause of the cardiac arrest, or time to ROSC (Fig. 3).
Fig. 3
Pooled results of early versus delayed coronary angiography trials on all-cause death across subgroups. Prolonged time to ROSC was defined as > 15 min (except for COACT > 30 min). Legend: CAG coronary angiography; OR odds ratio; CI confidence interval
×
Discussion
The present trial-level meta-analysis of 1512 patients with OHCA and no ST-segment elevation showed that a strategy of early/immediate versus delayed/selective coronary angiography did not reduce the risk of all-cause death. This finding was consistent across tested subgroups, including patients with and without an ischemic event as the presumed cause of the cardiac arrest. However, a strategy of early/immediate coronary angiography tended to be associated with increased odds of death in women as compared with men.
Anzeige
This meta-analysis included previously unreported data for subgroups and thus updates and expands on previous meta-analyses [20, 21]. The present findings corroborate that a strategy of early coronary angiography is not superior over a strategy of delayed/selective coronary angiography in OHCA patients without ST-segment elevation. Moreover, early coronary angiography may cause harm by increasing the odds of death in certain patient subgroups. There are several possibilities that may explain these findings. First, only a subset of patients (35%) required coronary revascularization and thus derived possible benefit from the performed procedure. These numbers imply that a non-selective “one size fits all” approach that refers all OHCA patients without ST-segment elevation to coronary angiography is not favorable. Future research should be directed at the early identification of patients with OHCA who may benefit from coronary revascularization. The majority of patients who did not require coronary revascularization was exposed to increased risk of peri- and postprocedural complications of coronary angiography, including bleeding events, stroke, or worsening of kidney function, although the complication rates were small across the included trials, and there was no significant difference between the treatment groups. Moreover, patients with OHCA frequently require hemodynamic monitoring, ventilation, and early initiation of targeted temperature management. An early invasive coronary angiography approach may result in delay of essential quality critical care. In the COACT and TOMAHAWK trials, targeted temperature management was initiated on average approximately 30 to 60 min earlier in patients assigned to the delayed/selective strategy arm than in those randomized to the early strategy arm [1, 10]. The notion of a lack of benefit from immediate coronary angiography is also consistent with randomized controlled trials in non-ST-segment elevation myocardial infarction patients without cardiac arrest [22, 23].
The present study suggests that early coronary angiography is associated with higher odds of death in women than in men. This adds to the body of evidence of sex-based differences in outcomes after OHCA. Although women are less likely than men to develop coronary artery disease, and their severity of coronary artery disease is lower in OHCA [24, 25], they have a greater risk of major adverse cardiovascular events following percutaneous coronary intervention than men [15]. Importantly, women made up only one-fourth of the trial population. It is therefore crucial to increase the proportion of women participating in clinical trials to ensure equal representation.
In the present meta-analysis, comprising more than 1,500 patients across 5 randomized trials among patients with OHCA and no ST-elevation on the initial ECG, we were unable to identify any subgroup of patients, based on demographics or clinical presentation, which derived potential benefit from an early invasive strategy. Whether specific subgroups of patients not explored here may derive potential benefit remains unclear. The ongoing DISCO (Direct or Subacute Coronary Angiography in Out-of-hospital Cardiac Arrest; ClinicalTrials.gov Identifier: NCT02309151) trial will provide further insight into sex differences and potential identification of other high-risk subgroups.
Limitations
Several limitations of this meta-analysis need to be acknowledged. This was a trial level meta-analysis of five randomized controlled trials rather than individual participant study level data. The definitions and time points of immediate/early and delayed/selective coronary angiography as well as the follow-up varied between trials. Moreover, we were not able to investigate additional subgroups of interest, such as those stratified by baseline LVEF, interventional access site, severity of coronary artery disease, or cardiac biomarker concentrations. Furthermore, the study is limited by the absence of information regarding timing and use of dual antiplatelet therapy regimens, guideline directed medical therapy, and medications at discharge. In addition, baseline characteristics, mode of death, and endpoints beyond all-cause death have not been reported for subgroups. Although all trials included in the present meta-analysis were well conducted, treating clinicians were aware of treatment assignment by the inherent nature of the trial design. Moreover, cross-over rates ranged between 14 and 31% across the trials and the follow up times differed. Lastly, all trials excluded patients with ST-segment elevation or in-hospital cardiac arrest, and only a limited number of patients with hemodynamic or electrical instability were included.
Anzeige
Conclusions
In conclusion, there was no statistically significant difference between immediate/early and delayed/selective coronary angiography in OHCA patients without ST-segment elevation with regard to all-cause mortality or neurologic impairment. We did not identify any subgroup of patients, based on demographics or clinical presentation, which derived potential benefit from an early invasive strategy. Though, women tended to have higher odds of death with early/immediate coronary angiography than men.
Declarations
Conflict of interest
FH has no conflicts of interest. EA has no conflicts of interest. CS reports no conflict of interest with this study. CHB reports receiving grants from the French Ministry of Health during the conduct of the study. AV reports no conflict of interest with this study. AVT has no conflicts of interest. BAB reports grant support through institution: Pfizer, Ionis, AstraZeneca, Abbott Vascular, Philips, Medtronic. Consulting fees: Abiomed, Abbott Vascular, SpectraWAVE, Endovascular Engineering, Bain Life Sciences, Terumo. DLB discloses the following relationships—Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; Board of Directors: Angiowave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Consultant: Broadview Ventures, Hims; Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio; Royalties: Elsevier (Editor, Braunwald’s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Takeda. RHM reports research grants and personal fees from AstraZeneca, Bayer, Biomm and Servier; and research grants from Amgen, Pfizer, EMS, Aché, CytoDin, Brazilian Ministry of Health, University Health Network (received from his institution), and Lemann Foundation Research Fellowship. PLM reports research grants from South-Eastern Norway Regional Health Authority and honoraria for serving on advisory boards, consulting and/or speaker fees from Amarin, AmGen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Novartis, Novo Nordisk, Pharmacosmos, Us2.ai and Vifor. IML has relationships with drug companies including AOP-Health, Actelion-Janssen, MSD, United Therapeutics, Medtronic, Neutrolis and Ferrer. NF reports honoraria for serving on advisory boards from Boehringer Ingelheim, and lecture fees from AstraZeneca, Bayer, Novartis and Pfizer. TAZ reports research grants from the Austrian Science Funds and the German Research Foundation, honoraria for serving on advisory boards from Boehringer Ingelheim, personal fees from AstraZeneca, Boehringer Ingelheim, and Sun Pharmaceutical Industries, and educational grants from Eli Lilly and Company.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
(“Out-of-Hospital Cardiac Arrest” [Mesh] OR “OHCA” [tiab] OR “Out-of-Hospital Cardiac arrest” [tiab] OR “heart arrest” [tiab]) AND (“coronary angiography” [Mesh] OR “coronary angiogram” [tiab] OR “PCI” [tiab] OR “CAG” [tiab]) AND (random*[tw] OR “Letter”[pt] OR “trial” [tiab]) NOT (“Review” [ptyp]).
Embase search
(‘out of hospital cardiac arrest’/exp OR ‘out of hospital cardiac arrest’:ti,ab OR ‘OHCA’:ti,ab) AND (‘coronary angiography’/exp OR ‘coronary angiography’:ti,ab OR ‘PCI’:ti,ab OR ‘coronary angiogram’:ti,ab OR ‘percutaneous coronary intervention’:ti,ab) AND (‘trial’:ti,ab) NOT (‘chapter’/it OR ‘conference review’/it OR ‘editorial’/it OR ‘review’/it OR ‘meta-analysis’:ti).
Electronic supplementary material
Below is the link to the electronic supplementary material.
Early versus delayed coronary angiography in patients with out-of-hospital cardiac arrest and no ST-segment elevation: a systematic review and meta-analysis of randomized controlled trials
verfasst von
Fardin Hamidi Elaaha Anwari Christian Spaulding Caroline Hauw-Berlemont Aurélie Vilfaillot Ana Viana-Tejedor Karl B. Kern Chiu-Hsieh Hsu Brian A. Bergmark Arman Qamar Deepak L. Bhatt Remo H. M. Furtado Peder L. Myhre Christian Hengstenberg Irene M. Lang Norbert Frey Anne Freund Steffen Desch Holger Thiele Michael R. Preusch Thomas A. Zelniker
Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.
In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.
Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.
In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.
Update Kardiologie
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
